Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
March 20, 2018 12:50 PM
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
